Tiotropium + olodaterol versus tiotropium on breathlessness during 3-minute CSST in COPD

Phase 4, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in intensity of breathlessness at the end of the 3-minute Constant Speed Shuttle Test. Started Jun 2016; status: completed.